Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma.

Fonteyne P, Casneuf V, Pauwels P, Van Damme N, Peeters M, Dierckx R, Van de Wiele C.

Histol Histopathol. 2009 Aug;24(8):971-7.

PMID:
19554504
2.

Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography.

Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K.

Cancer Sci. 2008 Feb;99(2):260-6. doi: 10.1111/j.1349-7006.2007.00683.x.

3.

Expression and prognostic value of glucose transporters and hexokinases in tonsil and mobile tongue squamous cell carcinoma.

Deron P, Vermeersch H, Mees G, Vangestel C, Pauwels P, Van de Wiele C.

Histol Histopathol. 2011 Sep;26(9):1165-72.

PMID:
21751148
4.

Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.

Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K.

Int J Oncol. 2008 Nov;33(5):1047-54.

PMID:
18949368
5.

Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer.

Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, Kudo H, Matsubara K, Gunji H, Ochiai T.

Hepatogastroenterology. 2005 Mar-Apr;52(62):486-90.

PMID:
15816463
6.

18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.

Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, Boellaard R, van Lanschot JJ, Molthoff CF.

J Cancer Res Clin Oncol. 2008 Feb;134(2):227-36. Epub 2007 Jul 25.

PMID:
17653575
7.

Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors.

Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B, Pinchera A, Elisei R.

Mol Cell Endocrinol. 2008 Sep 10;291(1-2):57-62. doi: 10.1016/j.mce.2008.05.003. Epub 2008 May 14.

PMID:
18571834
8.

Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography.

Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC.

Nucl Med Commun. 2009 Aug;30(8):594-601. doi: 10.1097/MNM.0b013e32832cc295.

PMID:
19536037
9.

Differential expression of facilitative glucose transporters in normal and tumour kidney tissues.

Suganuma N, Segade F, Matsuzu K, Bowden DW.

BJU Int. 2007 May;99(5):1143-9.

11.

Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle.

Stuart CA, Yin D, Howell ME, Dykes RJ, Laffan JJ, Ferrando AA.

Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1067-73. Epub 2006 Jun 27.

12.

Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.

Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE.

Nucl Med Biol. 2009 Feb;36(2):191-7. doi: 10.1016/j.nucmedbio.2008.11.009.

PMID:
19217531
13.

FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumour proliferation and apoptosis.

Deron P, Vangestel C, Goethals I, De Potter A, Peeters M, Vermeersch H, Van de Wiele C.

Nuklearmedizin. 2011;50(1):15-21. doi: 10.3413/nukmed-0324-10-06. Epub 2010 Nov 5.

PMID:
21052609
14.

Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.

Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F.

J Cell Physiol. 2006 Jun;207(3):614-27.

PMID:
16523487
15.

The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma.

Hiyoshi Y, Watanabe M, Imamura Y, Nagai Y, Baba Y, Yoshida N, Toyama E, Hayashi N, Baba H.

Oncology. 2009;76(4):286-92. doi: 10.1159/000207505. Epub 2009 Mar 5.

PMID:
19262068
16.

Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response.

Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schrattenholz A, Cahill MA, Schwaiger M, Hofler H, Wester HJ.

Clin Cancer Res. 2008 Dec 15;14(24):8279-87. doi: 10.1158/1078-0432.CCR-08-0679.

17.

AEG I and II: is it one tumor entity?

Lenglinger J, Ringhofer C, Riegler M.

Ann Surg. 2008 Jun;247(6):1080-1; author reply 1081. doi: 10.1097/SLA.0b013e3181758d4b. No abstract available.

PMID:
18520245
18.

GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.

Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ.

Mod Pathol. 2006 Nov;19(11):1429-36. Epub 2006 Aug 4.

19.

Expression of conventional and novel glucose transporters, GLUT1, -9, -10, and -12, in vascular smooth muscle cells.

Pyla R, Poulose N, Jun JY, Segar L.

Am J Physiol Cell Physiol. 2013 Mar;304(6):C574-89. doi: 10.1152/ajpcell.00275.2012. Epub 2013 Jan 9.

20.

Kinetics of transport and phosphorylation of glucose in cancer cells.

Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Moreno-Sánchez R.

J Cell Physiol. 2009 Dec;221(3):552-9. doi: 10.1002/jcp.21885.

PMID:
19681047
Items per page

Supplemental Content

Write to the Help Desk